Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This could go to $1 ....IMO
This is huge news, looks like not many ppl knows about this yet.
Smart knows the value and holding tight, this is not PnD, you have to wait to get rewarded.
Great DD stervc as always, Holding strong here and adding more next week
Agree... adding more here.
Great news.....!!!!!
Tomorrow kaboooooom time
Wow what a bid. 0018 now. Flying time
Strong Bid...over 002 soon
Lets go
Kaboooooom soon
Great DD, good future, i am buying today.
$NPHC Strong Bid.. 2.4 Mil Vol already..!!!!
$NPHC Strong Bid.. 1.4Mil Vol already..!!!!
$NPHC Strong Bid.. Flying..!!!!
$NPHC flying.....!!!!!
If you watching L2 you can see MMs trying their old game
many dont know about this yet, wait till after noon and then kaaboooooom
L2 looks good.
$$HMSO....300% UP Merger NEWS soon
$$HMSO....300% UP Merger NEWS soon
Looks like 0.1 soooon
0.009 UP
http://www.verimatrix.com/ WOW Great NEWS
$$$HMSO...Merger NEWS-- 200% UP
HMSO...Merger soon.. NEW CEO..200% UP
HMSO...Merger soon.. NEW CEO..200% UP
$NEIK 150% UP
$NEIK 150% UP
Super thin MMs wont be able to hold it for long now
Looks like NEWS over the weekend or Monday
0.005 ASK Weeeeeeeeeeeeeeeeeeeeeeee
Nice looks like who ever missed today will try to rush to buy tomorrow.. OMG
The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015
Propanc Health Group Targets Cancer Patient Trials in 2015
MELBOURNE, Australia, May 16, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc Health Group," "Propanc" or "the Company"), a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers.
Dr Kenyon, Chief Scientific Officer of Propanc Health Group, states, "After a detailed strategic review of our scientific and preclinical research, our development team determined I.V. injection as the preferred route of administration. This approach would be the best way to maximise results in future patient trials, by ensuring maximum exposure of the drug to the tumor site."
James Nathanielsz, Chief Executive Officer of Propanc Health Group, said, "We believe this will help us to improve the results already observed in a Compassionate Use Study conducted by Dr Kenyon at the Dove Clinic (UK). We were able to extend life in a number of terminally ill patients, free from the serious side effects normally observed during conventional treatment methods."
Based on the Company's strategic review, Propanc Health Group will conduct a number of animal studies in various tumor models. This will identify a target dose for future patient trials. "Once we have assessed and identified the most effective dose in animals, we plan to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015," said Professor Klaus Kutz, Chief Medical Officer at Propanc Health Group. "Depending on the final indication selected for our initial patient trials, we may also seek Orphan Drug Designation for our treatment given the novelty of our proenzyme formulation and depending on the size of the target patient population we propose for trials."
The Company is seeking to complete the relevant animal studies and undertake preparation for patient trials next year. "Undertaking these development activities is a critical step for our future plans for the Company," James Nathanielsz, CEO of Propanc Health Group acknowledged. "Our attention will now turn toward raising the capital needed to complete these activities."
Propanc Health Group aims to fast-track the development of proenzyme-related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015, according to Global Analyst Reports.
About Propanc Health Group Corporation
L2 looks great, strong bid all hidden, MMs wants it bad
0.01 sooooooooon
Added more see ya at 0.01 land
My bid is still not getting filled, l2 looks strong